We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · October 13, 2020

Exemestane With or Without Enzalutamide in Patients With HR-Positive Breast Cancer

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-Positive Breast Cancer
Clin. Cancer Res 2020 Sep 28;[EPub Ahead of Print], I Krop, VG Abramson, M Colleoni, TA Traina, FA Holmes, L Garcia-Estevez, L Hart, A Awada, C Zamagni, PG Morris, LS Schwartzberg, SY Chan, A Gucalp, L Biganzoli, J Steinberg, L Sica, ME Trudeau, D Markova, JC Tarazi, Z Zhu, T O'Brien, C Kelly, EP Winer, D Yardley

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading